BBIO News and Press, BridgeBio Pharma Inc. From 01/09/26

2026-01-09 11:25:07 ET BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study January 9, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Di...

2026-01-08 08:05:37 ET from Truist Financial issued a price target of $86.00 for BBIO on 2026-01-08 12:53:20. The adjusted price target was set to $86.00. At the time of the announcement, BBIO was trading at $74.27. The overall price target consensus is at $88.22 with hi...

PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at t...

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, January ...

2025-12-25 21:40:55 ET This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 11/14/2025. Please visit our ...

2025-12-23 12:41:26 ET Shares of BridgeBio ( BBIO ) have appreciated considerably this year. The stock has more than doubled since my first public article November 2024 and is up more than 160% since my February update . BridgeBio was one of my Top Picks in the Growth St...

2025-12-22 16:07:25 ET More on healthcare stocks My S&P 500 Prediction On Sector Outperformers And Laggards In 2026 Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026 IHI: A Passive ETF For Medical Device Exposure PACS G...

2025-12-17 12:29:56 ET Fast Facts About the Direxion Daily S&P Biotech Bull 3X ETF Read the full article on Seeking Alpha For further details see: LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF

2025-12-13 22:45:00 ET The last three months have been a little more challenging for Alnylam Pharmaceuticals (ALNY), with slowing sales at a key rival raising concerns about the overall health of the critical transthyretin amyloidosis (or TTR) space, particularly with more competition l...

2025-12-11 05:06:16 ET from Bernstein issued a price target of $94.00 for BBIO on 2025-12-11 09:54:18. The adjusted price target was set to $94.00. At the time of the announcement, BBIO was trading at $72.7. The overall price target consensus is at $83.71 with high price...